Abstract
Background and objective: TZP-101 is a selective, small molecule ghrelin receptor agonist in clinical development for the treatment of gastric motility disorders. The objectives of this study was to assess pharmacokinetic parameters of TZP-101 after multiple- and single-dose administration to healthy subjects and patients with gastroparesis, respectively, and to determine the contribution of protein binding to its pharmacokinetic behaviour.
Methods: Pharmacokinetics following 30-minute intravenous infusions of single (160–600 µg/kg) doses of TZP-101 in patients with gastroparesis and multiple (80–600 µg/kg/day) doses of TZP-101 in healthy subjects were characterized. TZP-101 protein binding was measured in human, dog, rat, rabbit and monkey plasma using equilibrium dialysis.
Results: TZP-101 pharmacokinetic profiles were less than dose proportional in both healthy subjects and patients, most likely because of concentrationdependent protein binding. A small volume of distribution (99–180 µL/kg following single doses) and long half-life (10–20 hours) were concentration independent in both healthy subjects and patients. Systemic clearance increased with increasing dose. Incidence of adverse events was not related to dose or treatment (active vs placebo). TZP-101 binding to human plasma proteins (primarily α1-acid glycoprotein) was ≥99% between 5 and 15 µmol/L (2.7 and 8.1 µg/mL) and was significantly higher than in other species.
Conclusions: The pharmacokinetic parameters of TZP-101 in patients with gastroparesis and healthy subjects are comparable and display a similar trend toward increased clearance at higher dose levels resulting in little accumulation of TZP-101 at high dose levels and after multiple dosing. Significant protein binding indicates that the fraction of free drug rather than the total plasma concentration should be taken into consideration for human risk assessment based on animal safety data. Furthermore, the concentration of unbound drug should be considered when optimizing the clinical dose.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Date Y, Kojima M, Hosoda H, et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000; 141(11): 4255–61
Edholm T, Levin F, Hellstrom PM, et al. Ghrelin stimulates motility in the small intestine of rats through intrinsic cholinergic neurons. Regul Pept 2004; 121(1-3): 25–30
Fukuda H, Mizuta Y, Isomoto H, et al. Ghrelin enhances gastric motility through direct stimulation of intrinsic neural pathways and capsaicin-sensitive afferent neurones in rats. Scand J Gastroenterol 2004; 39(12): 1209–14
Murray CD, Martin NM, Patterson M, et al. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut 2005; 54(12): 1693–8
Tack J, Depoortere I, Bisschops R, et al. Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment Pharmacol Ther 2005; 22(9): 847–53
Binn M, Albert C, Gougeon A, et al. Ghrelin gastrokinetic action in patients with neurogenic gastroparesis. Peptides 2006; 27(7): 1603–6
Bytzer P, Talley NJ, Leemon M, et al. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15 000 adults. Arch Intern Med 2001; 161(16): 1989–96
Abell TL, Bernstein RK, Cutts T, et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil 2006; 18(4): 263–83
Camilleri M. Clinical practice: diabetic gastroparesis. N Engl J Med 2007; 356(8): 820–9
Artinyan A, Nunoo-Mensah JW, Balasubramaniam S, et al. Prolonged postoperative ileus: definition, risk factors, and predictors after surgery. World J Surg 2008; 32(7): 1495–500
Traut U, Brugger L, Kunz R, et al. Systemic prokinetic pharmacologic treatment for postoperative adynamic ileus following abdominal surgery in adults. Cochrane Database Syst Rev 2008; (1): CD004930
Ankersen M, Kramer Nielsen K, Kruse Hansen T, et al. Growth hormone secretagogues derived from NN703 with hydrazides as c-terminal. Eur J Med Chem 2000; 35(5): 487–97
Venkova K, Fraser G, Hoveyda HR, et al. Prokinetic effects of a new ghrelin receptor agonist TZP-101 in a rat model of postoperative ileus. Dig Dis Sci 2007; 52(9): 2241–8
Lasseter KC, Shaughnessy L, Cummings D, et al. Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers. A phase I, firstin-human study. J Clin Pharmacol 2008; 48(2): 193–202
Ejskjaer N, Vestergaard E, Hellstrom P, et al. Ghrelin agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis: an exploratory, randomized, placebo-controlled, double-blind study. Aliment Pharm Ther. Epub 2009 Feb 27
Acharya MR, Sparreboom A, Sausville EA, et al. Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. Cancer Chemother Pharmacol 2006; 57(3): 275–81
Fuse E, Kuwabara T, Sparreboom A, et al. Review of UCN-01 development: a lesson in the importance of clinical pharmacology. J Clin Pharmacol 2005; 45(4): 394–403
Otagiri M. A molecular functional study on the interactions of drugs with plasma proteins. Drug Metab Pharmacokinet 2005; 20(5): 309–23
Fuse E, Tanii H, Takai K, et al. Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans. Cancer Res 1999; 59(5): 1054–60
Sparreboom A, Chen H, Acharya MR, et al. Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine. Clin Cancer Res 2004; 10(20): 6840–6
Hedaya MA, Daoud SS. Tissue distribution and plasma pharmacokinetics of UCN-01 at steady-state and following bolus administration in rats: influence of human alpha1-acid glycoprotein binding. Anticancer Res 2001; 21(6A): 4005–10
Nakagawa T, Kishino S, Itoh S, et al. Differential binding of disopyramide and warfarin enantiomers to human alpha(1)-acid glycoprotein variants. Br J Clin Pharmacol 2003; 56(6): 664–9
Grandison MK, Boudinot FD. Age-related changes in protein binding of drugs: implications for therapy. Clin Pharmacokinet 2000; 38(3): 271–90
Higai K, Azuma Y, Aoki Y, et al. Altered glycosylation of alpha1-acid glycoprotein in patients with inflammation and diabetes mellitus. Clin Chim Acta 2003; 329(1–2): 117–25
Kishino S, Nomura A, Zhai S, et al. Alpha-1-acid glycoprotein concentration and the protein binding of disopyramide in healthy subjects. J Clin Pharmacol 1995; 35(5): 510–4
Acknowledgements
Funding for the design and conduct of the study and collection and analysis of the data was provided by Tranzyme Pharma, Inc., Durham, NC, USA. Helmut Thomas, Lilian Clohs, Carl St-Louis, Laura Shaughnessy and Gordana Kosutic are employees of Tranzyme Pharma, Inc. Niels Ejskjaer is an advisory board member for Tranzyme Pharma, Inc. William Wargin is a consultant for Tranzyme. Maria Gutierrez has no conflicts of interest that are directly relevant to the content of this study. Patrice Ferriola, PhD provided writing and editing assistance, and was supported by Tranzyme Pharma, Inc.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wargin, W., Thomas, H., Clohs, L. et al. Contribution of Protein Binding to the Pharmacokinetics of the Ghrelin Receptor Agonist TZP-101 in Healthy Volunteers and Adults with Symptomatic Gastroparesis. Clin. Drug Investig. 29, 409–418 (2009). https://doi.org/10.2165/00044011-200929060-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-200929060-00004